Go to the list of all blogs
Allana's Avatar
published in Blogs
Jul 30, 2026
Why Is Teladoc Health (TDOC) Stock Down -27.23% Today?

Why Is Teladoc Health (TDOC) Stock Down -27.23% Today?

Key Takeaways

  • Teladoc Health shares plummeted 27.23% in Thursday's session after the company reported a second-quarter revenue miss and slashed its full-year guidance.
  • The primary catalyst was Q2 revenue of $606.9 million falling short of the $615.4 million Wall Street consensus, coupled with sharply reduced forward revenue projections.
  • BetterHelp's accelerating cash-pay decline took center stage, with the mental health segment's direct-to-consumer revenue deteriorating faster than management had anticipated.
  • Competitive headwinds from OpenAI's expanded ChatGPT health features added a layer of sector-wide pressure on telehealth names.
  • High short interest of nearly 16% of float likely amplified the selloff as bearish positioning paid off dramatically.
  • Traders are now watching whether the company's accelerated insurance rollout at BetterHelp can stabilize revenue trends in the second half of the year.

Opening Summary

TDOC, the stock of Teladoc Health, Inc.—the global leader in virtual care services spanning primary care, mental health, and chronic condition management—suffered its worst single-day percentage decline since February 2024 on Thursday. Shares closed the prior session at $9.18 but cratered to approximately $6.68 in intraday trading, marking a stunning drop of roughly 27%. The selloff was triggered by second-quarter 2026 earnings released after the bell on Wednesday, which revealed a revenue miss and a significant cut to full-year guidance, overwhelming any optimism around the company's narrower-than-expected loss per share.

Q2 Earnings Miss and Deteriorating BetterHelp Revenue

Teladoc Health reported second-quarter 2026 consolidated revenue of $606.9 million, down 4% year-over-year and below the $615.4 million consensus estimate. While the company posted a smaller-than-expected net loss of $0.21 per share—beating estimates for a $0.25 loss—investors zeroed in squarely on the top-line shortfall and the weakening trajectory of the BetterHelp direct-to-consumer mental health platform.

BetterHelp segment revenue came in at $212.6 million, representing a 12% year-over-year decline. CEO Chuck Divita acknowledged that cash-pay revenue pressure "accelerated further in late May and into June," beyond the assumptions underlying the company's prior outlook. Although insurance-covered demand for BetterHelp services exceeded expectations, provider capacity constraints limited the company's ability to convert that demand into sessions and revenue. The segment's adjusted EBITDA margin collapsed to just 0.2%, underscoring the profitability squeeze.

Full-Year Guidance Slashed

Perhaps most damaging to investor confidence was the steep reduction in full-year revenue guidance. Teladoc now expects fiscal 2026 revenue in the range of $2.362 billion to $2.447 billion, representing a year-over-year decline of 3% to 7%. At the midpoint, this implies a roughly 5% cut from prior expectations. Third-quarter revenue guidance of $569 million to $609 million also came in below Street forecasts, signaling that management does not expect a quick turnaround.

The guidance cut reflects updated assumptions for BetterHelp's cash-pay business, with management explicitly stating it is prioritizing the growing insurance market over stabilizing the legacy direct-pay model. While the strategic pivot toward insurance may strengthen long-term positioning, the near-term revenue erosion has rattled the market.

Competitive Pressure From AI and Sector Sentiment

Adding to the bearish narrative, OpenAI launched an expanded Health experience inside ChatGPT for U.S. users on the same day, allowing individuals to link medical records, lab results, and wearable data into conversational AI interactions. Both TDOC and peer AMWL (American Well) retreated on Thursday, as investors weighed the risk that AI-driven tools could erode demand for paid virtual consultations for lower-acuity informational needs. While Teladoc concurrently unveiled Teladoc One—a connected virtual care model integrating AI—the announcement was overshadowed by the earnings fallout and the broader competitive overhang.

Market Context and Trading Activity

The magnitude of Thursday's decline was extraordinary by any measure. The stock gapped below its 30-day moving average, a key technical level that had provided support since May. Trading volume was set to finish dramatically above the daily average, reflecting capitulation-style selling. The selloff landed TDOC on the short-sale restricted (SSR) list, and with short interest already sitting at 15.96% of the float—equivalent to roughly six days of buying power—the move likely featured an element of momentum-driven liquidation. The broader healthcare and telehealth sector felt the ripple effects, but Teladoc's decline far outpaced peers, confirming that company-specific fundamentals drove the action.

What Comes Next for TDOC

Looking ahead, all eyes will be on Teladoc's execution of its accelerated insurance rollout at BetterHelp. Management continues to expect 2026 insurance revenue within its previously communicated range, but the success of rapidly scaling provider capacity to meet insurance-driven demand remains a critical question mark. The Integrated Care segment, which posted 1% revenue growth and a 16.5% adjusted EBITDA margin, offers a modest bright spot, but it is not large enough to offset BetterHelp's challenges on its own.

Upcoming catalysts include any signs of stabilization in BetterHelp monthly active user trends, further details on Teladoc One adoption rates when select clients begin using the platform in September 2026, and third-quarter results that will test whether the lowered guidance bar proves conservative or merely the first of further cuts. With 19 of 26 analysts already at "Hold" ratings prior to the earnings debacle, further downgrades could add selling pressure in the days ahead.

Trending AI Robots

In volatile market environments like today's, traders increasingly turn to data-driven tools to navigate rapid price swings. Tickeron's Trending AI Robots page spotlights a curated selection of AI-powered trading bots from a universe of hundreds covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots spanning diverse strategies, timeframes, and performance metrics across numerous symbols. For traders seeking algorithmic insights, exploring the Trending AI Robots page offers a window into which strategies are resonating in the current market environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TDOC

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


TDOC sees MACD Histogram crosses below signal line

TDOC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 17, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TDOC as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

TDOC moved below its 50-day moving average on July 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for TDOC crossed bearishly below the 50-day moving average on August 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TDOC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TDOC's RSI Oscillator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TDOC advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

TDOC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 170 cases where TDOC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.886) is normal, around the industry mean (7.638). TDOC has a moderately low P/E Ratio (0.000) as compared to the industry average of (46.808). TDOC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.726). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. P/S Ratio (0.459) is also within normal values, averaging (6.460).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TDOC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TDOC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.95B. The market cap for tickers in the group ranges from 708 to 40.27B. VEEV holds the highest valuation in this group at 40.27B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was 1%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 25%. TEM experienced the highest price growth at 40%, while ONMD experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 4%. For the same stocks of the Industry, the average monthly volume growth was -51% and the average quarterly volume growth was -90%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 76
Price Growth Rating: 52
SMR Rating: 86
Profit Risk Rating: 98
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
TDOC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a telephone and online video consultation service

Industry ServicestotheHealthIndustry

Profile
Details
Industry
Hospital Or Nursing Management
Address
2 Manhattanville Road
Phone
+1 203 635-2002
Employees
5600
Web
https://www.teladochealth.com
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.